Non-Small-Cell Lung Carcinomas
Showing 1 - 25 of >10,000
Lung Tumor Protein Synthesis Rates in Lung Cancer Patients
Recruiting
- Lung Cancer
- There are no interventions in the present study
-
Heerlen, Limburg, NetherlandsZuyderland Medical Center
Mar 31, 2023
NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +3 more
- Montanide (Registered Trademark) ISA-51 VG Adjuvant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Lung Sarcomatoid Carcinoma Trial in Beijing, Shanghai (Savolitinib)
Active, not recruiting
- Lung Sarcomatoid Carcinoma
-
Beijing, Beijing, China
- +1 more
Nov 29, 2021
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer Trial in Japan, United States (PF-07265028, Sasanlimab)
Recruiting
- Advanced Solid Tumors
- +5 more
- PF-07265028
- Sasanlimab
-
Scottsdale, Arizona
- +7 more
Jan 23, 2023
Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Chiba, Tokyo (RO7616789, Tocilizumab)
Recruiting
- Small Cell Lung Cancer
- Neuroendocrine Carcinoma
-
Chiba, Japan
- +1 more
Jan 16, 2023
Small Cell Lung Cancer Trial in Nice (acetazolamide in combination with platinum and etoposide-based radiochemo)
Recruiting
- Small Cell Lung Cancer
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy
-
Nice, FranceCentre Antoine Lacassagne
Jan 19, 2023
Double-dose Furmonertinib in Treatment of Slow
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- (no location specified)
Oct 31, 2023
NSCLC Trial in Shanghai
Not yet recruiting
- Non-small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Jul 20, 2023
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Toripalimab
- +2 more
-
Yangzhou, Jiangsu, ChinaPeople's hospital of northern jiangsu
Sep 26, 2023
Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)
Not yet recruiting
- Stage II-IIIB(N2) Non-small Cell Lung Cancer
- TQB2450
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 26, 2023
Specific Protein Overexpression in Adult Non-Small Cell Lung
Not yet recruiting
- Non Small Cell Lung Cancer
- (no location specified)
Sep 29, 2023
Identify Resected Non-small-cell Lung Cancer With High Risk of
Recruiting
- Non-small Cell Lung Cancer Stage IIIA
- Resected non small cell lung cancer
-
Toulouse, FranceJulien MAZIERES
Feb 8, 2023
NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tirelizumab;Chemotherapy monotherapy
- (no location specified)
Jul 27, 2023
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy
Not yet recruiting
- Lung Cancer, Non-small Cell
- Small Cell Lung Cancer
- (no location specified)
Nov 16, 2022
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Crizotinib - Usual
- Crizotinib - Study
-
Rockville, MarylandMedicine Invention Design, Inc. - IORG0007849
Oct 5, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 2, 2023
NSCLC Trial in Beijing
Recruiting
- NSCLC
-
Beijing, ChinaYuyan Wang
Oct 10, 2023
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)
Recruiting
- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
NSCLC Trial in Guangzhou (BL-M07D1)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 1, 2023